DeepMed Research

Conjupro Biotherapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding, Subsidiary

Established: 2017-01-01

Employees: 11

Market Cap: -

Website: http://www.conjuprobio.com

Clinical Trials

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Cancer
Cancer, Lung

Interventions: Drug: CPO301

First Posted Date: 2023-07-17

Last Posted Date: 2024-07-03

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Target Recruit Count: 102

Registration Number: NCT05948865

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States

and more 10 locations

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Phase 1

Withdrawn

Conditions: Gastric Cancer
Pancreatic Cancer

Interventions: Drug: CPO102

First Posted Date: 2021-09-14

Last Posted Date: 2023-09-07

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Registration Number: NCT05043987

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: CPO-100

First Posted Date: 2021-06-18

Last Posted Date: 2024-08-28

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Target Recruit Count: 126

Registration Number: NCT04931823

Locations: 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States

and more 5 locations

Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma

Phase 1

Terminated

Conditions: CD20 Positive Non Hodgkin Lymphoma

Interventions: Drug: CPO107

First Posted Date: 2021-04-21

Last Posted Date: 2025-03-30

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Target Recruit Count: 7

Registration Number: NCT04853329

Locations: 🇺🇸
Novant Health, Charlotte, North Carolina, United States

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Phase 2

Withdrawn

Conditions: Peripheral Neuropathy
Breast Cancer

Interventions: Drug: Placebo
Drug: NBP Softgel Capsules

First Posted Date: 2020-12-19

Last Posted Date: 2023-06-08

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Registration Number: NCT04675450

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Levamlodipine, Amlodipine
Drug: Amlodipine, Levamlodipine

First Posted Date: 2018-09-05

Last Posted Date: 2021-09-16

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT03657550

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

Phase 1

Withdrawn

Conditions: Asthma

Interventions: Drug: HA115
Drug: Placebo

First Posted Date: 2018-06-26

Last Posted Date: 2021-09-08

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Registration Number: NCT03567694

Locations: 🇺🇸
CNS Network, Long Beach, California, United States

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Phase 1

Withdrawn

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: PLM60

First Posted Date: 2018-06-12

Last Posted Date: 2020-10-19

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Registration Number: NCT03553914

Locations: 🇺🇸
Gabrial Cancer Center, Canton, Ohio, United States
🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy